Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|November 24, 2025
VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunityMark R Schwartz, Nareen Z Anwar, Lydia E Kitelinger, et al.
JCO Oncology Practice|August 12, 2020
Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain MetastasesJulio Silvestre, Tracey Gosse, Paul Read, et al.
The Oncologist|September 21, 2012
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumorsAustin J Combest, Patrick J Roberts, Patrick M Dillon, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancerPatrick M Dillon, Gina R Petroni, Mark E Smolkin, et al.
Physiological Reports|February 18, 2026
The effect of two remote exercise programs on cardiorespiratory fitness, cardiac function, and vascular health in patients with breast cancerNathan R Weeldreyer, Charles C Ellison, Mckenzie B Mabalot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsPatrick J Roberts, Jerry E Usary, David B Darr, et al.
JAMA Dermatology|July 27, 2017
Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic MelanomaSteven Vernali, Weston T Waxweiler, Patrick M Dillon, et al.
Frontiers in Oncology|April 4, 2022
Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 TherapyAlexandra R Harris, Savieay Esparza, Mohammad S Azimi, et al.
JAMA Dermatology|August 28, 2014
Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based studyNancy E Thomas, Anne Kricker, Weston T Waxweiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Pageof 4